Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Atara Biotherapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Atara Biotherapeutics, Inc.’s stock price such as:

• Atara Biotherapeutics, Inc.’s current stock price and volume
• Why Atara Biotherapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for ATRA from analysts
• ATRA’s stock price momentum as measured by its relative strength

About Atara Biotherapeutics, Inc. (ATRA)

Before we jump into Atara Biotherapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Want to learn more about Atara Biotherapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Atara Biotherapeutics, Inc..

Atara Biotherapeutics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Atara Biotherapeutics, Inc.’s stock price was $8.380.

Atara Biotherapeutics, Inc. is up 2.57% from its previous closing price of $8.170.

During the last market session, Atara Biotherapeutics, Inc.’s stock traded between $7.860 and $8.670. Currently, there are approximately 14.08 million shares outstanding for Atara Biotherapeutics, Inc..

Atara Biotherapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Atara Biotherapeutics, Inc. Stock Price History

Atara Biotherapeutics, Inc.’s (ATRA) price is currently down 27% so far this month.

During the month of July, Atara Biotherapeutics, Inc.’s stock price has reached a high of $12.000 and a low of $7.390.

Over the last year, Atara Biotherapeutics, Inc. has hit prices as high as $19.145 and as low as $3.920. Year to date, Atara Biotherapeutics, Inc.’s stock is down 53.68%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Atara Biotherapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of July 31, 2026,, no analysts have changed their rating of Atara Biotherapeutics, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Atara Biotherapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Atara Biotherapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Atara Biotherapeutics, Inc. (ATRA) by visiting AAII Stock Evaluator.

Relative Price Strength of Atara Biotherapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Atara Biotherapeutics, Inc. has a weighted four-quarter relative price strength of 13.89%, which translates to a Momentum Score of 87 and is considered to be Very Strong.

Want to learn more about how Atara Biotherapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Atara Biotherapeutics, Inc. Stock Price: Bottom Line

As of July 31, 2026, Atara Biotherapeutics, Inc.’s stock price is $8.380, which is up 2.57% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Atara Biotherapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.